Site Editor

Gregory J. Riely, MD, PhD

Aaron Lisberg, MD, on TROPION-Lung01 Trial and Antibody-Drug Conjugates

Posted: Thursday, February 1, 2024

Aaron Lisberg, MD, of the University of California, Los Angeles, discusses the findings of the TROPION-Lung01 trial and comparing the antibody-drug conjugate datopotamab deruxtecan with standard therapies for advanced or metastatic NSCLC.

JNCCN Spotlights

(UPDATE) Nivolumab in NSCLC

Dabrafenib + Trametinib

Sotorasib

(NEW Update) Pembrolizumab in NSCLC

Resources

For your Patients

Free ME from Lung Cancer

Lung Cancer Research Council, Inc.

LUNGevity Foundation

Caring Ambassadors Program

Sections

360 Hub

NCCN Resources

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.